KCT0008411尚未招募Unknown
A Multicenter, Prospective, Open-label, Randomized Controlled Study to Evaluate the Safety of Short-term Dual Antiplatelet Therapy after Coronary Stenting with the Everolimus-Eluting Stent in Patients with Coronary artery disease
适应症
试验速览
- 阶段
- Unknown
- 状态
- 尚未招募
- 入组人数
- 2,018
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 19(Year) 至 o Limit（—）
- 性别
- All
入选标准
- •? Adults 19 years of age or older
- •? Patients with coronary artery disease requiring coronary intervention
- •? Patients who underwent percutaneous coronary intervention with centum stent, everolimus-eluting stent
排除标准
- •? Subjects with known history of severe hypersensitivity reactions to aspirin, clopidogrel, everolimus, contrast agent
- •? If there is clinically active bleeding at the time of study enrollment (active bleeding)
- •? Subjects who underwent stenting in the unprotected left main coronary artery
- •? Subjects whose life expectancy is less than 1 year for reasons other than cardiovascular disease
- •? Pregnant or lactating women
- •? If it is difficult to maintain dual antiplatelet therapy for anticoagulant treatment due to atrial fibrillation, etc.
- •? Inability to provide informed consent
研究者
相似试验
招募中
3 期
A Prospective, Open-label, Multicenter, Randomized Study to Evaluate the Benefits and Risks of Conversion of Existing Adolescent Renal Allograft Recipients Aged 12 to Less Than 18 Years of Age to a Belatacept-based Immunosuppressive Regimen as Compared to Continuation of a Calcineurin Inhibitor-based Regimen, and Their Adherence to Immunosuppressive MedicationsKidney transplantRenal Allograft10038430NL-OMON52226Bristol-Myers Squibb3
进行中（未招募）
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and their Compliance with Immunosuppressive MedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-000237-12-FRBristol-Myers Squibb International Corporation120
招募中
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression inAdolescent Renal Transplant Recipients and their Compliance with ImmunosuppressiveMedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code: 10038533Term: Renal transplant Class: 100000004865CTIS2022-501677-39-00Bristol Myers Squibb International Corporation109
进行中（未招募）
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and their Compliance with Immunosuppressive MedicationsAdolescent Renal AllograftsMedDRA version: 21.0Level: PTClassification code 10038533Term: Renal transplantSystem Organ Class: 10042613 - Surgical and medical proceduresEUCTR2018-000237-12-NLBristol-Myers Squibb International Corporation120
进行中（未招募）
1 期
Evaluation of Conversion from Calcineurin Inhibitor- to Belatacept-based Immunosuppression in Adolescent Renal Transplant Recipients and their Compliance with Immunosuppressive MedicationsEUCTR2018-000237-12-DEBristol-Myers Squibb International Corporation120